Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs

The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir–ritonavir) for the early treatment of SARS‐2 COVID‐19‐positive patients aged 12 years and over who ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Svedmyr, Anders, Hack, Henrik, Anderson, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Educational Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543968/
https://www.ncbi.nlm.nih.gov/pubmed/35842922
http://dx.doi.org/10.1111/pan.14529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543968/
https://www.ncbi.nlm.nih.gov/pubmed/35842922
http://dx.doi.org/10.1111/pan.14529

Ejemplares similares